Researchers at McMaster University and the Massachusetts Institute of Technology (MIT), led by McMaster assistant professor Jon Stokes, have identified a new antibiotic that could offer a more targeted approach to treating inflammatory bowel disease (IBD), including Crohn’s disease.
Named enterololin, the antibiotic selectively attacks a family of bacteria associated with intestinal infections while sparing beneficial gut bacteria. Its discovery could help address a limitation of existing antibiotics, which can disrupt the gut microbiome and create opportunities for drug-resistant bacteria to thrive.
In a further breakthrough, Stokes and his collaborators used artificial intelligence (AI) to predict how the antibiotic works, with subsequent laboratory experiments confirming the model’s findings. The approach reduced the time required for mechanism-of-action research from up to two years to just six months, demonstrating how AI could accelerate the development of new treatments.
A more targeted antibiotic for IBD
Most antibiotics currently used in clinical settings have broad-spectrum activity, meaning they target harmful bacteria but can also destroy beneficial microorganisms living in the gut.
This disruption can leave the intestinal environment vulnerable to colonisation by invasive and drug-resistant bacteria, including Escherichia coli (E. coli). These organisms can contribute to the worsening of conditions such as Crohn’s disease.
Enterololin offers a different approach. Developed at McMaster, the antibiotic has a narrow spectrum of activity, targeting Enterobacteriaceae, a family of bacteria that includes E. coli, rather than affecting the wider gut microbiome.
By selectively eliminating these bacteria, the drug could also reduce opportunities for antibiotic-resistant strains to establish themselves in the intestines.
The discovery represents a potential new direction for developing an antibiotic for IBD, although further research and clinical testing will be needed before its suitability for patients can be established.
AI predicts how the antibiotic works
Alongside identifying enterololin, the researchers demonstrated a new application for AI in pharmaceutical development.
AI has increasingly been used to screen chemical compounds and identify molecules with potential therapeutic properties. However, establishing precisely how a promising drug candidate works has remained a significant challenge.
Known as mechanism-of-action (MOA) research, this process is essential for understanding how a drug interacts with its target. It also helps researchers assess safety, determine appropriate dosages, improve effectiveness and identify potential new treatment targets.
Traditional MOA investigations can take up to two years and cost approximately $2m.
To accelerate the process, Stokes contacted colleagues at MIT’s Computer Science and Artificial Intelligence Laboratory to explore whether emerging machine learning platforms could help with the investigation.
Using DiffDock, an AI model developed by MIT professor Regina Barzilay, the researchers received a prediction about enterololin’s mechanism of action in just 100 seconds.
The model suggested that the antibiotic targeted LolCDE, a microscopic protein complex essential to the survival of certain bacteria.
Laboratory experiments confirm AI prediction
The prediction provided researchers with a starting point for investigating the drug, but experimental validation remained necessary.
Led in large part by McMaster PhD candidate Denise Catacutan, the team conducted conventional laboratory investigations to establish whether enterololin acted through the predicted pathway.
The experiments confirmed that the AI model had correctly identified its target.
By using the prediction to guide their investigations, researchers completed the MOA work in six months, cutting approximately 18 months from the conventional development timeline. The cost was also reduced from around $2m to $60,000.
The findings demonstrate how AI could help address one of the more time-consuming and expensive stages of drug development, moving beyond identifying potential drug candidates to explaining how they function.
Enterololin moves towards human trials
The next stage will focus on preparing the antibiotic for potential clinical use.
Stokes’ spin-out company, Stoked Bio, has licensed enterololin from McMaster University and is working to optimise the drug for human use.
The company is also investigating modified versions of the antibiotic against other drug-resistant bacteria, including Klebsiella, with early results described as promising.
Researchers hope enterololin could be ready to enter human trials within three years.
For people living with Crohn’s disease and other forms of IBD, the research offers a promising avenue for investigating treatments that target problematic bacteria without unnecessarily disrupting the wider gut microbiome.